[144] Arcus Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Arcus Biosciences (RCUS) insider holders filed a notice to sell 50,000 shares of Class A common stock through Goldman Sachs & Co. LLC on the NYSE, with an indicated aggregate market value of $999,500. The filing states that 120,801,086 shares of this class were outstanding at the time referenced, providing context for the planned sale size. The shares were originally acquired from the issuer in private transactions in May 2015. Over the past three months, the same trust has already sold additional Class A shares in several transactions, including 77,167 shares on 10/29/2025 for gross proceeds of $1,617,034.48. The signer represents that they are not aware of undisclosed material adverse information about the company.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	50000	999500	120801086	11/17/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	05/29/2015	Acquired from issuer in private transaction	The Issuer			22396	05/29/2015	None
Class A Common Stock	05/08/2015	Acquired from issuer in private transaction	The Issuer			27604	05/08/2015	None

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Class A Common Stock	10/28/2025	19019	372011.64
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Class A Common Stock	10/29/2025	673	14102.71
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Class A Common Stock	10/29/2025	77167	1617034.48
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Class A Common Stock	10/30/2025	4314	87638.91

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Arcus Biosciences (RCUS) disclose?

The filing discloses that an insider-related trust plans to sell 50,000 shares of Arcus Biosciences Class A common stock through Goldman Sachs & Co. LLC on the NYSE, with an indicated aggregate market value of $999,500.

How many Arcus Biosciences (RCUS) shares are outstanding in this filing?

The Form 144 notes that there were 120,801,086 shares of Arcus Biosciences Class A common stock outstanding at the time referenced, which is a baseline figure separate from the shares being sold.

Who is selling Arcus Biosciences (RCUS) shares in this Form 144 and how were they acquired?

The seller is identified as The Juan Carlos Jaen and Anita Galeana 2000 Trust. The shares to be sold were acquired from the issuer in private transactions in May 2015, with blocks of 22,396 and 27,604 shares acquired on 05/29/2015 and 05/08/2015, respectively.

What recent sales of Arcus Biosciences (RCUS) stock has the trust made?

Over the past three months, the trust has sold several blocks of Class A common stock, including 19,019 shares on 10/28/2025, 673 shares and 77,167 shares on 10/29/2025, and 4,314 shares on 10/30/2025, for gross proceeds such as $1,617,034.48 on the 77,167-share sale.

Which broker will handle the planned Arcus Biosciences (RCUS) share sale?

The planned sale of 50,000 shares of Arcus Biosciences Class A common stock will be handled by Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY 10282, with the securities listed on the NYSE.

What representation does the seller make about Arcus Biosciences (RCUS) information?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer's current or prospective operations that has not been publicly disclosed.